Issa Mohamad, Fawzi Abu-Hijleh, Ebrahim Mayta, Taher Abu-Hejleh, Wisam Al-Gargaz, Abdellatif Al Mousa, Ramiz Abu-Hijlih, Ali Hosni
{"title":"Comparison of Two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma.","authors":"Issa Mohamad, Fawzi Abu-Hijleh, Ebrahim Mayta, Taher Abu-Hejleh, Wisam Al-Gargaz, Abdellatif Al Mousa, Ramiz Abu-Hijlih, Ali Hosni","doi":"10.1055/s-0042-1742724","DOIUrl":null,"url":null,"abstract":"<p><p>Issa Mohamad<b>Objectives</b> To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC). <b>Methods</b> Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated. <b>Results</b> A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1, <i>p</i> < 0.01), late G II brain toxicity (4 vs. 1, <i>p</i> < 0.01), and late G II dysphagia (32 vs. 11, <i>p</i> = 0.01). <b>Conclusions</b> Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"11 3","pages":"223-228"},"PeriodicalIF":0.6000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/3a/10-1055-s-0042-1742724.PMC9803531.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"South Asian Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1742724","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Issa MohamadObjectives To compare outcomes and toxicity of two standard treatment approaches of advanced nasopharyngeal carcinoma (NPC). Methods Between 2010 and 2016, patients with NPC, stage II-IVa, treated with induction chemotherapy (IC) (TPF), followed by concurrent chemoradiotherapy (CCRT) (induction group), or CCRT, followed by adjuvant chemotherapy (AC) (PF) (no-induction group), were retrospectively reviewed. CCRT included platinum-based chemotherapy with intensity-modulated radiotherapy. Survival outcomes, the pattern of failures, toxicity, and predictors for survival outcomes were evaluated. Results A total of 110 patients were included, 65 in the induction group and 45 in the no-induction group. There were no significant differences in the DFS and overall survival (OS) at 3 years between the two groups. On multivariate analysis, performance status (1 vs. 0) predicted worse OS. The 3-year cumulative incidence rates for local, regional, and distant failures were 58.5% (95% confidence interval [CI]: 8.4-89%), 58.00% (95% CI: 8-88.8%), and 63.90% (95% CI: 14.1-90.2%), respectively. IC had more frequent acute grade (G) II anemia (13 vs. 1, p < 0.01), late G II brain toxicity (4 vs. 1, p < 0.01), and late G II dysphagia (32 vs. 11, p = 0.01). Conclusions Survival outcomes were comparable between the two groups. IC had more frequent acute G II anemia and late G II brain and esophageal toxicities.
目的比较两种标准治疗晚期鼻咽癌(NPC)的疗效和毒性。方法回顾性分析2010 - 2016年期间,接受诱导化疗(IC) +同步放化疗(CCRT)(诱导组)或CCRT +辅助化疗(AC) (PF)(非诱导组)治疗的II-IVa期鼻咽癌患者。CCRT包括铂基化疗加调强放疗。对生存结果、失败模式、毒性和生存结果的预测因素进行评估。结果共纳入110例患者,其中诱导组65例,非诱导组45例。两组患者的DFS和3年总生存期(OS)无显著差异。在多变量分析中,性能状态(1 vs. 0)预示着更差的OS。局部、区域和远处失败的3年累积发病率分别为58.5%(95%可信区间[CI]: 8.4-89%)、58.00% (95% CI: 8-88.8%)和63.90% (95% CI: 14.1-90.2%)。IC患者急性(G) II级贫血发生率更高(13 vs. 1, p p p = 0.01)。结论两组患者的生存结局具有可比性。IC有更频繁的急性G期贫血和晚期G期脑和食管毒性。